<p>Mirum Pharmaceuticals, Inc.（納斯達克代碼：MIRM - 獲取免費報告）在週六的午盤交易中創下了 52 周的新高，此前 Citizens Jmp 將該股的目標價從 95.00 美元上調至 140.00 美元。Citizens Jmp 目前對該股的評級為市場表現優於大盤。Mirum Pharmaceuticals 的股價最高達到 79.95 美元，最後交易價為 77.74 美元，成交量為 3828816 股。該股此前收盤價為 70.28 美元。</p>
<p>獲取 <strong>Mirum Pharmaceuticals</strong> 的提醒：</p>
<p>其他一些分析師也最近對該股發表了評論。Evercore ISI 在 12 月 8 日的研究報告中將 Mirum Pharmaceuticals 的目標價從 89.00 美元上調至 94.00 美元，並給予公司 “表現優於大盤” 的評級。Wall Street Zen 在 9 月 26 日的研究報告中將 Mirum Pharmaceuticals 的評級從 “買入” 上調至 “強力買入”。JMP Securities 在 11 月 5 日的研究報告中對 Mirum Pharmaceuticals 設定了 95.00 美元的目標價。摩根大通在 9 月 12 日的研究報告中將 Mirum Pharmaceuticals 的目標價從 53.00 美元上調至 77.00 美元，並給予該股 “增持” 評級。最後，花旗集團在週五的報告中重申了對 Mirum Pharmaceuticals 的 “表現優於大盤” 評級。兩位投資分析師給予該股 “強力買入” 評級，十二位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “買入”，共識目標價為 100.25 美元。</p>
<p><strong>獲取我們關於 Mirum Pharmaceuticals 的最新報告</strong></p>
<h2>對 Mirum Pharmaceuticals 的對沖基金看法</h2>
<p>一些機構投資者最近調整了對該公司的持股。Tudor Investment Corp ET AL 在第三季度購買了價值約 202.7 萬美元的 Mirum Pharmaceuticals 新股份。CIBC Bancorp USA Inc.在第三季度購買了價值約 31.5 萬美元的 Mirum Pharmaceuticals 新股份。PharVision Advisers LLC 在第三季度購買了價值約 27.3 萬美元的 Mirum Pharmaceuticals 新股份。Virtus Advisers LLC 在第三季度購買了價值約 29.3 萬美元的 Mirum Pharmaceuticals 新股份。最後，Voleon Capital Management LP 在第三季度購買了價值 634.3 萬美元的 Mirum Pharmaceuticals 新股份。</p>
<h2>Mirum Pharmaceuticals 上漲 10.6%</h2>
<p>該公司的 50 日簡單移動平均線為 70.49 美元，200 日簡單移動平均線為 64.45 美元。公司的速動比率為 3.16，流動比率為 3.31，債務與股本比率為 1.06。該股的市值為 40 億美元，市盈率為-90.39，貝塔值為 0.42。</p>
<p>Mirum Pharmaceuticals（納斯達克代碼：MIRM - 獲取免費報告）最後一次公佈季度財報是在 11 月 4 日，報告顯示該季度每股收益為 0.05 美元，超出市場共識預期的-0.10 美元 0.15 美元。該季度公司的收入為 1.3301 億美元，而分析師預期為 1.3011 億美元。Mirum Pharmaceuticals 的股本回報率為-16.47%，淨利潤率為-8.78%。該公司的季度收入較去年同期增長了 47.1%。在去年同期，該公司每股收益為-0.30 美元。股票分析師預測 Mirum Pharmaceuticals, Inc.在本年度將發佈-1.43 美元的每股收益。</p>
<h2>關於 Mirum Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Mirum Pharmaceuticals, Inc 是一家處於後期階段的生物製藥公司，致力於開發和商業化針對罕見膽汁淤積性肝病的創新療法。該公司的主要關注點是解決患有遺傳性和進行性兒童肝病患者未滿足的醫療需求，目前治療選擇有限。</p>
<p>Mirum 的主要產品候選藥物 maralixibat（Livmarli）是一種腸道膽鹽轉運蛋白抑制劑，旨在減少全身膽鹽的積累，並緩解相關的瘙癢和肝損傷。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Mirum Pharmaceuticals</li>
<li>電動車股票及其盈利方式</li>
<li>耐克財報超預期，但在中國市場面臨挑戰並遭遇關税</li>
<li>紐約證券交易所與納斯達克的區別，以及這對投資者的重要性</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票表示不是</li>
<li>如何交易便士股票：逐步指南</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Mirum Pharmaceuticals 嗎？</h2>
<p>在考慮 Mirum Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Mirum Pharmaceuticals 並不在名單上。</p>
<p>雖然 Mirum Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

MIRM

<p>Mirum Pharmaceuticals（納斯達克代碼：MIRM）在 Citizens Jmp 將其目標價從 95 美元上調至 140 美元，並維持市場跑贏大盤評級後，達到了新的 52 周高點。該股交易最高達到 79.95 美元，收盤價為 77.74 美元，較 70.28 美元上漲。分析師對該股給予了一致的 “買入” 評級，目標價為 100.25 美元。機構投資者最近調整了他們的持股，該公司報告的季度每股收益為 0.05 美元，超出預期</p>

<p>Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) hit a new 52-week high during mid-day trading on Saturday after Citizens Jmp raised their price target on the stock from $95.00 to $140.00. Citizens Jmp currently has a market outperform rating on the stock. Mirum Pharmaceuticals traded as high as $79.95 and last traded at $77.74, with a volume of 3828816 shares traded. The stock had previously closed at $70.28.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals, Inc.（納斯達克代碼：MIRM - 獲取免費報告）在週六的午盤交易中創下了 52 周的新高，此前 Citizens Jmp 將該股的目標價從 95.00 美元上調至 140.00 美元。Citizens Jmp 目前對該股的評級為市場表現優於大盤。Mirum Pharmaceuticals 的股價最高達到 79.95 美元，最後交易價為 77.74 美元，成交量為 3828816 股。該股此前收盤價為 70.28 美元。</p>
</div><p>Get <strong>Mirum Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Mirum Pharmaceuticals</strong> 的提醒：</p>
</div><p>A number of other analysts have also recently commented on the stock. Evercore ISI upped their price target on shares of Mirum Pharmaceuticals from $89.00 to $94.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 8th. Wall Street Zen raised Mirum Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Friday, September 26th. JMP Securities set a $95.00 target price on Mirum Pharmaceuticals in a research report on Wednesday, November 5th. JPMorgan Chase &amp; Co. raised their target price on Mirum Pharmaceuticals from $53.00 to $77.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, September 12th. Finally, Citigroup reiterated an &#34;outperform&#34; rating on shares of Mirum Pharmaceuticals in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $100.25.</p>
<div class="lb-trans"><p>其他一些分析師也最近對該股發表了評論。Evercore ISI 在 12 月 8 日的研究報告中將 Mirum Pharmaceuticals 的目標價從 89.00 美元上調至 94.00 美元，並給予公司 “表現優於大盤” 的評級。Wall Street Zen 在 9 月 26 日的研究報告中將 Mirum Pharmaceuticals 的評級從 “買入” 上調至 “強力買入”。JMP Securities 在 11 月 5 日的研究報告中對 Mirum Pharmaceuticals 設定了 95.00 美元的目標價。摩根大通在 9 月 12 日的研究報告中將 Mirum Pharmaceuticals 的目標價從 53.00 美元上調至 77.00 美元，並給予該股 “增持” 評級。最後，花旗集團在週五的報告中重申了對 Mirum Pharmaceuticals 的 “表現優於大盤” 評級。兩位投資分析師給予該股 “強力買入” 評級，十二位給予 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “買入”，共識目標價為 100.25 美元。</p>
</div><p><strong>Get Our Latest Report on Mirum Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Mirum Pharmaceuticals 的最新報告</strong></p>
</div><h2>Hedge Funds Weigh In On Mirum Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Mirum Pharmaceuticals 的對沖基金看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of the company. Tudor Investment Corp ET AL bought a new position in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $2,027,000. CIBC Bancorp USA Inc. bought a new position in Mirum Pharmaceuticals in the 3rd quarter worth approximately $315,000. PharVision Advisers LLC purchased a new position in Mirum Pharmaceuticals in the 3rd quarter valued at approximately $273,000. Virtus Advisers LLC purchased a new position in Mirum Pharmaceuticals in the 3rd quarter valued at approximately $293,000. Finally, Voleon Capital Management LP bought a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at $6,343,000.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了對該公司的持股。Tudor Investment Corp ET AL 在第三季度購買了價值約 202.7 萬美元的 Mirum Pharmaceuticals 新股份。CIBC Bancorp USA Inc.在第三季度購買了價值約 31.5 萬美元的 Mirum Pharmaceuticals 新股份。PharVision Advisers LLC 在第三季度購買了價值約 27.3 萬美元的 Mirum Pharmaceuticals 新股份。Virtus Advisers LLC 在第三季度購買了價值約 29.3 萬美元的 Mirum Pharmaceuticals 新股份。最後，Voleon Capital Management LP 在第三季度購買了價值 634.3 萬美元的 Mirum Pharmaceuticals 新股份。</p>
</div><h2>Mirum Pharmaceuticals Trading Up 10.6%</h2>
<div class="lb-trans"><h2>Mirum Pharmaceuticals 上漲 10.6%</h2>
</div><p>The firm has a 50-day simple moving average of $70.49 and a 200-day simple moving average of $64.45. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The stock has a market cap of $4.00 billion, a PE ratio of -90.39 and a beta of 0.42.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 70.49 美元，200 日簡單移動平均線為 64.45 美元。公司的速動比率為 3.16，流動比率為 3.31，債務與股本比率為 1.06。該股的市值為 40 億美元，市盈率為-90.39，貝塔值為 0.42。</p>
</div><p>Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analysts' expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm's quarterly revenue was up 47.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.30) earnings per share. Equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals（納斯達克代碼：MIRM - 獲取免費報告）最後一次公佈季度財報是在 11 月 4 日，報告顯示該季度每股收益為 0.05 美元，超出市場共識預期的-0.10 美元 0.15 美元。該季度公司的收入為 1.3301 億美元，而分析師預期為 1.3011 億美元。Mirum Pharmaceuticals 的股本回報率為-16.47%，淨利潤率為-8.78%。該公司的季度收入較去年同期增長了 47.1%。在去年同期，該公司每股收益為-0.30 美元。股票分析師預測 Mirum Pharmaceuticals, Inc.在本年度將發佈-1.43 美元的每股收益。</p>
</div><h2>About Mirum Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Mirum Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.</p>
<div class="lb-trans"><p>Mirum Pharmaceuticals, Inc 是一家處於後期階段的生物製藥公司，致力於開發和商業化針對罕見膽汁淤積性肝病的創新療法。該公司的主要關注點是解決患有遺傳性和進行性兒童肝病患者未滿足的醫療需求，目前治療選擇有限。</p>
</div><p>Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.</p>
<div class="lb-trans"><p>Mirum 的主要產品候選藥物 maralixibat（Livmarli）是一種腸道膽鹽轉運蛋白抑制劑，旨在減少全身膽鹽的積累，並緩解相關的瘙癢和肝損傷。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Mirum Pharmaceuticals</li>
<li>EV Stocks and How to Profit from Them</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>How to trade penny stocks: A step-by-step guide</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Mirum Pharmaceuticals</li>
<li>電動車股票及其盈利方式</li>
<li>耐克財報超預期，但在中國市場面臨挑戰並遭遇關税</li>
<li>紐約證券交易所與納斯達克的區別，以及這對投資者的重要性</li>
<li>人工智能熱潮是泡沫嗎？這兩隻分紅股票表示不是</li>
<li>如何交易便士股票：逐步指南</li>
<li>2026 年四隻高潛力 ETF：小型股、太空股票等</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Mirum Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Mirum Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Mirum Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Mirum Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Mirum Pharmaceuticals 並不在名單上。</p>
</div><p>While Mirum Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Mirum Pharmaceuticals 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Mirum Pharmaceuticals（NASDAQ:MIRM）在分析師上調評級後創下新的 52 周高點